AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense
July 14, 2025
AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts. On July 3, the company provided an update to its 2025 earnings guidance to account for a pre-tax acquired in-process research and development (IPR&D) and milestones expense of $823 million in the second quarter of 2025. This expense is expected to reduce both GAAP diluted earnings per share (EPS) and adjusted non-GAAP diluted EPS by $0.42 for the second quarter. Also, the company updated its full-year 2025 adjusted diluted EPS guidance to a range of $11.67 to $11.87, incorporating the $823 million IPR&D expense.
AbbVie Shares Climb on $700 Million Licensing Deal with IGI Therapeutics
July 10, 2025
AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing exclusive global rights to develop and commercialize ISB 2001 — a promising multispecific antibody candidate targeting cancer and autoimmune conditions.
Under the terms of the deal, AbbVie will make an upfront payment of $700 million to IGI Therapeutics, a subsidiary of Ichnos Glenmark Innovation, Inc., based in New York. The agreement also includes up to $1.225 billion in potential milestone payments linked to development, regulatory, and commercial achievements. IGI is further entitled to receive tiered double-digit royalties on future net sales of ISB 2001.
ISB 2001 was developed using IGI’s proprietary BEAT® protein engineering platform and represents a novel trispecific antibody approach in immuno-oncology. AbbVie views the molecule as a potential game-changer in the treatment of multiple myeloma and other conditions where conventional therapies fall short.
“Multispecifics — including trispecific antibodies — are emerging as a transformative class in immuno-oncology, capable of engaging multiple targets to deliver deeper and more durable treatment responses,” said Dr. Roopal Thakkar, Executive Vice President and Chief Scientific Officer at AbbVie.
This strategic partnership strengthens AbbVie’s oncology pipeline and reinforces its investment in next-generation biologics. The transaction is pending regulatory approval before the agreement becomes effective.
The market responded positively to the announcement, reflecting confidence in AbbVie’s R&D strategy and its commitment to expanding its presence in high-growth therapeutic areas.
AbbVie stock price This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Market Data 
Markets 
AI
